Cerebral Palsy

In February 2007, the Company entered into an agreement with Galephar Pharmaceutical Research to develop and market a combination of Pravastatin and Fenofibrate for mixed dyslipedemia.

Mixed dyslipidemia is the presence of elevated levels of triglycerides and low-density lipoprotein (LDL), or "bad" cholesterol, and low levels of high-density lipoproteins (HDL), or "good" cholesterol in the blood.

In April 2007, the Company began enrolling patients in a pivotal Phase III study that will compare the combination of pravastatin and fenofibrate to pravastatin alone and fenofibrate alone.

The Company plans to launch an improved formulation of Optinate, a prenatal vitamin with DHA, during the second quarter of 2007.

Guidance for Full-Year 2007 Sciele Pharma is increasing its full-year 2007 revenue and earnings guidance.

Revenues for the full-year 2007 are expected to be in the range of $365 million to $390 million.

This increase reflects higher revenues from products acquired from Alliant Pharmaceuticals and the launch of the new Optinate formulation and represents an expected increase of 25% to 33% over full-year 2006.

The Company expects full-year 2007 diluted earnings per share to be in the range of $1.60 to $1.70, including approximately $1.5 million in restructuring charges related to the Alliant acquisition, which represents an expected increas...

Read more...